Skip to main content

Empagliflozin Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on May 13, 2024.

Applies to empagliflozin: oral tablet.

Serious side effects of Empagliflozin

Along with its needed effects, empagliflozin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking empagliflozin:

More common

Less common


Incidence not known

Other side effects of Empagliflozin

Some side effects of empagliflozin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to empagliflozin: oral tablet.


The most common adverse reactions (incidence of greater than 5%) were urinary tract infections, female genital mycotic infections, hypoglycemia, and adverse reactions related to volume depletion. Pediatric patients experienced a higher incidence of hypoglycemia.[Ref]


Postmarketing reports: Hypotension


Common (1% to 10%): Pruritus, rash

Postmarketing reports: Skin reactions including angioedema and urticaria


Common (1% to 10%): Nausea

Postmarketing reports: Constipation


Very common (10% or more): Female urinary tract infections (up to 18.4%)

Common (1% to 10%): Female genital mycotic infections, increased urination, male urinary tract infections

Uncommon (0.1% to 1%): Phimosis, male genital mycotic infections, nocturia, dysuria

Postmarketing reports: Urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene)


Common (1% to 10%): Increased hematocrit


Frequency not reported: Hepatic injury


Postmarketing reports: Angioedema, hypersensitivity reactions


Very common (10% or more): Hypoglycemia, especially in combination with other glucose lowering therapies (up to 41.3%), adverse reactions related to volume depletion (up to 11.4%)

Common (1% to 10%): Increased low-density lipoprotein cholesterol, dyslipidemia

Postmarketing reports: Ketoacidosis

The risk of hypoglycemia (i.e., blood glucose less than 54 mg/dL) was higher in pediatric patients.

Reactions related to volume depletion included decreased ambulatory blood pressure, decreased systolic blood pressure, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope with the highest rates occurring in patients with heart failure.

In clinical studies, ketoacidosis was not immediately recognized, especially in patients with type 1 diabetes, and treatment was delayed because presenting blood glucose levels were lower (often less than 250 mg/dL [14 mmol/l]) than those typically expected. In some, but not all cases, patients had an identifiable precipitating risk factor for ketoacidosis


Common (1% to 10%): Arthralgia


Common (1% to 10%): Thirst

Frequency not reported: Lower limb amputation


Very rare (less than 0.01%): Tubulo-interstitial nephritis

Frequency not reported: Increased serum creatinine, decreased estimated GFR

Postmarketing reports: Acute kidney injury, urosepsis, pyelonephritis


Common (1% to 10%): Upper respiratory tract infection

Frequently asked questions


1. (2023) "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim Ltd

2. (2023) "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, SUPPL-42

3. (2024) "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim Pty Ltd

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.